11.30.10
Results of a study presented in May at Digestive Disease Week (DDW) by Professor Philippe Ducrotté, from Rouen University Hospital, in France, demonstrated that the probiotic strain Lactobacillus plantarum 299v (LP299v) effectively relieves gastrointestinal symptoms, particularly abdominal pain and bloating, in Irritable Bowel Syndrome (IBS) patients fulfilling the Rome III criteria.
The randomized, placebo-controlled trial enrolled 214 patients (63 women and 151 men) fulfilling the Rome III criteria for IBS. The study was conducted over a four-week period and consisted of a daily capsule of placebo or Lp299v equivalent to 10 CFU/day. IBS symptoms were monitored, including frequency of abdominal pain, intensity of abdominal pain, bloating, number of stools and feeling of incomplete rectal evacuation.
After four weeks of treatment, Lp299v significantly improved the symptoms, in particular abdominal pain and bloating, as compared to both baseline and the placebo group. The overall patient’s assessment of the treatment was significantly better in the Lp299v group compared to the placebo group.
Jarrow Formulas’ Ideal Bowel Support 299v contains Probi’s proprietary probiotic strain Lactobacillus plantarum 299v (Lp299v), which has been shown in clinical trials to survive and colonize the digestive tract and alleviates intestinal discomfort in 95% of the patients studied.